drugset
drugset / Trial / NCT05801107

Study to Investigate the Efficacy and Safety of WX-0593 in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients

NCT05801107 ↗

Phase 2 Unknown 30 enrolled Qilu Pharmaceutical Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

The primary purpose of this study is to evaluate the efficacy and safety of WX-0593 in patients with ALK-positive NSCLC

Timeline

Start
2021-10-25
Primary completion
2023-07-15
Completion
2023-12-15

Drugs

EvaluationDrugModalityDoseRoute
Subject WX-0593 Small molecule 180 mg —

Indications

non-small cell lung carcinoma